Spenser Karr

Represented PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, in its auction and subsequent $1.85 billion sale to Thermo Fisher Scientific Inc. 

Represented Labcorp (NYSE: LH) in its acquisition of select assets of Invitae (OTC: NVTAQ), a leading medical genetics company. 

Represented a large, publicly-traded pharmaceutical company in its build-to-buy agreement for the development, potential acquisition, and potential milestone payments relating to a new drug compound

Represented Enstar Group Limited, a publicly traded company, in its negotiation of a $5.1 billion take-private transaction with Sixth Street.

Represented Medical Outcomes Research Analytics in its merger with Helix Technologies, Inc., and the formation of the successor entity, Forian, Inc. (Nasdaq: FORA). *

Represented a leading global financial institution in its investment in a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines. *

Represented a leading global financial institution in its investment in a biopharmaceutical company specializing in heart disease treatment. *

Represented Tissue Analytics in its sale to Net Health, a provider of cloud-based EHR software for specialized care settings. *

Represented a pharmaceutical company developing injectable products for the treatment of allergic reactions in its acquisition by a developer of specialty pharmaceutical products. *

Represented a biomedical marketing company in its negotiations of various contracts with major pharmaceutical companies. *

Represented a clinical stage biopharmaceutical company in the negotiation of clinical trial agreements with multiple research and educational institutions. *

Represented a clinical-trial stage U.S.-based developer of medical devices in its sale to a publicly-traded, global health technology company. *

Represents Emily’s Entourage, a non-profit organization focused on rare mutations of cystic fibrosis, in their partnerships with clinical trial organizations.

Represented Tenable Holdings, Inc. (Nasdaq: TENB), a cybersecurity provider, in its $160 million acquisition of Accurics, Inc., a pioneer in developing cloud-native security.